Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Moexipril hydrochloride
Drug ID BADD_D01485
Description Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Indications and Usage For the treatment of hypertension.
Marketing Status approved
ATC Code C09AA13
DrugBank ID DB00691
KEGG ID D00623
MeSH ID C058302
PubChem ID 54889
TTD Drug ID D00HDU
NDC Product Code 68462-208; 17404-0018; 0093-0017; 0093-5150; 66039-838; 68462-209
UNII Q1UMG3UH45
Synonyms moexipril | 2-((1-ethoxycarbony)-3-phenylpropylamino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | Fempress | moexipril hydrochloride | Univasc | Moex | Perdix | RS 10085 | RS-10085
Chemical Information
Molecular Formula C27H35ClN2O7
CAS Registry Number 82586-52-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.002--
Influenza22.07.02.001; 11.05.03.001--Not Available
Malaise08.01.01.003--
Mood altered19.04.02.007--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oliguria20.01.03.004--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Pemphigus23.03.01.005; 10.04.02.003--Not Available
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Rhinitis11.01.13.004; 22.07.03.006--
Sinusitis22.07.03.007; 11.01.13.005--
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tinnitus04.04.01.002; 17.04.07.004--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene